Showing results (291-300 of 606) with videos related to

Sort By:
Pageof 61
Pharmacoeconomics - Open|June 29, 2026
Availability, Prices, and Affordability of Immune Checkpoint Inhibitors: A Cross-Sectional Study in Anhui Province, ChinaTongming Zhu, Kunkun Ge, Aizong Shen, et al.
Pharmacoeconomics - Open|July 30, 2026
AMPLIFY: Estimating Clinical and Humanistic Benefits of Pembrolizumab in PortugalPedro Cardoso, Joana Sousa, João Ferreira, et al.
Pharmacoeconomics - Open|August 13, 2026
The Chronic Kidney Disease Care Model: Quantifying Management Strategies for Improving Patient Outcomes in the USAAndrew H Briggs, Ciaran N Kohli-Lynch, Adrian R Levy, et al.
Pharmacoeconomics - Open|January 28, 2025
Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung CancerLeila-Sophie Otten, Alessandra I G Buma, Berber Piet, et al.
Pharmacoeconomics - Open|January 23, 2025
Semaglutide 2.4 mg versus Liraglutide 3 mg for the Treatment of Obesity in Greece: A Short-Term Cost-Effectiveness AnalysisPanagiotis Papantoniou, Nikolaos Maniadakis
Pharmacoeconomics - Open|December 6, 2024
Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year DataAlison D Griffiths, Robert O Young, Yong Yuan, et al.
Pharmacoeconomics - Open|December 14, 2024
Comparing Different Implementation Strategies for Collaborative Dementia Care Management in Terms of Patients' Characteristics, Unmet Needs, and the Impact on Quality of Life and Costs in GermanyMoritz Platen, Wolfgang Hoffmann, Bernhard Michalowsky
Pharmacoeconomics - Open|November 22, 2024
Burden of Disease of Breast Cancer in Italy: A Real-World Data AnalysisF S Mennini, A Marcellusi, P Sciattella, et al.
Pharmacoeconomics - Open|November 11, 2024
CMS's Drug Price Negotiation Program 2023 Patient-Focused Listening Sessions: A Descriptive Analysis of Speaker RemarksJulie A Patterson, Tyler D Wagner, Rayan K Salih, et al.
Pharmacoeconomics - Open|November 6, 2024
Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line TreatmentYan Chen, Ella X Du, Manasvi Sundar, et al.
Pageof 61